BRG01
Nasopharyngeal carcinoma (EBV+)
Phase 2Active
Key Facts
About Biosyngen
Biosyngen builds first‑in‑class cell‑therapy platforms to treat solid‑tumor cancers with rapid, safe, and scalable manufacturing.
View full company profileNasopharyngeal carcinoma (EBV+)
Biosyngen builds first‑in‑class cell‑therapy platforms to treat solid‑tumor cancers with rapid, safe, and scalable manufacturing.
View full company profile